Literature DB >> 9191955

Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.

R Guerrini1, G Calo, A Rizzi, C Bianchi, L H Lazarus, S Salvadori, P A Temussi, D Regoli.   

Abstract

Nociceptin (NC) and some of its fragments as well as nociceptin-(1-13)-peptide amide [NC- (1-13)-NH2] and a series of its analogues were prepared and tested in the mouse vas deferens in an attempt to identify the sequences involved in the activation (message) and in the binding (address) of nociceptin to its receptor. The NC receptor that inhibits the electrically evoked twitches of the mouse vas deferens was demonstrated to be distinct from the delta opioid receptor, since naloxone and Dmt-Tic-OH (a selective delta opioid receptor antagonist) block the delta opioid receptor but have no effect on the nociceptin receptor. Results from structure-activity experiments suggest that (a) the entire sequence of NC may not be required for full biological activities, since NC(1-13)-NH2 is as active as NC; (b) fragments of NC have however to be amidated as in NC(1-13)-NH2 in order to be protected from degradation by proteases; (c) cationic residues (as Arg8,12, Lys9,13) appear to play a functional role, since their replacement with Ala in the sequence of NC(1-13)-NH2 leads to inactivity; (d) the N-terminal tetrapeptide Phe-Gly-Gly-Phe is essential for activity: its full length and flexibility appear to be required for NC receptor activation and/or occupation; (e) Phe4 and not Phe1 appears to be the residue involved in receptor activation, since the replacement of Phe1 with Leu has no effect, while that of Phe4 leads to inactivity. Results summarized in this paper indicate that the structural requirements of NC for occupation and activation of its receptor are different from that of opioids, particularly delta agonists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9191955     DOI: 10.1021/jm970011b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  51 in total

1.  Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens.

Authors:  R Bigoni; G Calo; R Guerrini; J W Strupish; D J Rowbotham; D G Lambert
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

3.  Release of orphanin FQ/nociceptin in the medial preoptic nucleus and ventromedial nucleus of the hypothalamus facilitates lordosis.

Authors:  Kevin Sinchak; Phoebe Dewing; Misty Cook; Paul Micevych
Journal:  Horm Behav       Date:  2006-12-22       Impact factor: 3.587

4.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

5.  The effects of new nociceptin analogs on the behavior of white rats.

Authors:  E A Chesnokova; P K Anokhin; A S Voronkova; N Yu Sarycheva; V A Dubynin; A A Kamenskii; L A Andreeva; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-05-08

6.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

7.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

8.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

9.  Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5.

Authors:  Valeria Camarda; Carmela Fischetti; Nicholas Anzellotti; Paola Molinari; Caterina Ambrosio; Evi Kostenis; Domenico Regoli; Claudio Trapella; Remo Guerrini; Salvadori Severo; Girolamo Calo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-28       Impact factor: 3.000

10.  Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?

Authors:  Laura Micheli; Elena Lucarini; Francesca Corti; Roberto Ciccocioppo; Girolamo Calò; Anna Rizzi; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Eur J Pharmacol       Date:  2018-01-31       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.